Bristol Myers Squibb Gross Profit 2010-2022 | BMY

Bristol Myers Squibb annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Bristol Myers Squibb gross profit for the quarter ending September 30, 2022 was $8.865B, a 5.01% decline year-over-year.
  • Bristol Myers Squibb gross profit for the twelve months ending September 30, 2022 was $36.838B, a 5.33% increase year-over-year.
  • Bristol Myers Squibb annual gross profit for 2021 was $36.445B, a 18.54% increase from 2020.
  • Bristol Myers Squibb annual gross profit for 2020 was $30.745B, a 70.17% increase from 2019.
  • Bristol Myers Squibb annual gross profit for 2019 was $18.067B, a 12.26% increase from 2018.
Bristol Myers Squibb Annual Gross Profit
(Millions of US $)
2021 $36,445
2020 $30,745
2019 $18,067
2018 $16,094
2017 $14,762
2016 $14,458
2015 $12,651
2014 $11,947
2013 $11,766
2012 $13,011
2011 $15,646
2010 $14,207
2009 $13,668
Bristol Myers Squibb Quarterly Gross Profit
(Millions of US $)
2022-09-30 $8,865
2022-06-30 $9,167
2022-03-31 $9,177
2021-12-31 $9,629
2021-09-30 $9,333
2021-06-30 $9,251
2021-03-31 $8,232
2020-12-31 $8,158
2020-09-30 $8,038
2020-06-30 $7,430
2020-03-31 $7,119
2019-12-31 $5,453
2019-09-30 $4,217
2019-06-30 $4,301
2019-03-31 $4,096
2018-12-31 $4,363
2018-09-30 $4,043
2018-06-30 $4,079
2018-03-31 $3,609
2017-12-31 $3,848
2017-09-30 $3,675
2017-06-30 $3,575
2017-03-31 $3,664
2016-12-31 $3,837
2016-09-30 $3,617
2016-06-30 $3,665
2016-03-31 $3,339
2015-12-31 $3,335
2015-09-30 $2,972
2015-06-30 $3,150
2015-03-31 $3,194
2014-12-31 $3,292
2014-09-30 $2,914
2014-06-30 $2,898
2014-03-31 $2,843
2013-12-31 $3,168
2013-09-30 $2,890
2013-06-30 $2,940
2013-03-31 $2,768
2012-12-31 $3,116
2012-09-30 $2,749
2012-06-30 $3,198
2012-03-31 $3,948
2011-12-31 $4,087
2011-09-30 $3,938
2011-06-30 $3,953
2011-03-31 $3,668
2010-12-31 $3,697
2010-09-30 $3,518
2010-06-30 $3,491
2010-03-31 $3,501
2009-12-31 $3,600
2009-09-30 $3,471
2009-06-30 $3,440
2009-03-31 $3,157
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $169.923B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $77.117B 9.67
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.058B 18.88
Ginkgo Bioworks Holdings (DNA) United States $3.317B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $2.305B 34.61
Biohaven (BHVN) United States $1.089B 0.00
Emergent Biosolutions (EBS) United States $0.608B 4.78
Zymeworks (ZYME) Canada $0.443B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.262B 0.00
Enzo Biochem (ENZ) United States $0.087B 0.00
SQZ Biotechnologies (SQZ) United States $0.038B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00